First Tracks Biotherapeutics: private placement of 6,106,870 shares

What happened On Oct 15, 2026, First Tracks Biotherapeutics entered into a securities purchase agreement with certain third party investors under which the company agreed to issue and sell 6,106,870 shares of its common stock at a purchase price of $32.75 per share. The aggregate gross proceeds to the company are expected to be approximately $200,000,000, before placement agent fees and other offering expenses. The private placement is expected to close on Oct 19, 2026, subject to customary closing conditions. At the closing, the company will enter into a registration rights agreement requiring it to file or confidentially submit a registration statement covering resale of the shares no later than 30 days following the closing. The company also issued a press release on Oct 15, 2026 announcing the private placement (Exhibit 99.1).

Key details

• 6,106,870 shares of common stock to be sold at $32.75 per share.
• Aggregate gross proceeds expected to be approximately $200,000,000.
• Expected closing date: Oct 19, 2026, subject to customary conditions.
• Company must file or confidentially submit a registration statement covering resale no later than 30 days after closing.

Why it may matter The filing reports Item 1.01 (entry into a material definitive agreement) relating to the securities purchase agreement and Item 3.02 (unregistered sales of equity securities) relating to the private placement, and Item 7.01 (Regulation FD disclosure) for the Oct 15, 2026 press release. This filing does not show why the insider traded or why the company acted.